Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev<sup>®</sup>) in South Korea, 2015-2019.

HS, Kim; Y, Oh; J, Korejwo; VB, Castells; K, Yang

doi:10.1007/s40121-020-00305-6

Public

Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev<sup>®</sup>) in South Korea, 2015-2019.

Shared by NobleBlocks on May 30, 2020 • 12:00 AM UTC

Authors:

Kim HS

Oh Y

Korejwo J

Abstract

<h4>Introduction</h4>The live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV; Imojev<sup>®</sup>) has been approved in South Korea for use in subjects aged ≥ 12 months since 2015. As part of the license agreement, a post-marketing surveillance study was undertaken to actively monitor...

Subject

Safety

Vaccine

Japanese encephalitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!